Debra Stephanie Barker
Director/Board Member chez BERGENBIO ASA
Fortune : 32 483 $ au 31/03/2024
Postes actifs de Debra Stephanie Barker
| Sociétés | Poste | Début | Fin |
|---|---|---|---|
| BERGENBIO ASA | Director/Board Member | 13/03/2019 | - |
| DESTINY PHARMA PLC | Director/Board Member | 01/01/2020 | - |
| Chief Executive Officer | 25/05/2023 | 01/09/2023 | |
| Independent Dir/Board Member | 01/01/2020 | 25/05/2023 | |
| CUREVAC N.V. | Director/Board Member | 22/06/2022 | - |
| ARIX BIOSCIENCE PLC | Director/Board Member | 10/08/2022 | - |
| Independent Dir/Board Member | 10/08/2022 | - | |
Hutman Diagnostics AG
 Hutman Diagnostics AG Medical SpecialtiesHealth Technology Hutman Diagnostics AG is a Swiss company that specializes in the development and management of in vitro diagnostics products. | Director/Board Member | - | - |
CureVac SE
 CureVac SE BiotechnologyHealth Technology CureVac SE engages in the development of tumor immunotherapy. Its pipeline include mRNA-based Cancer Immunotherapies; Protein-based therapies; and mRNA-based Prophylactic Vaccines. The company was founded by Ingmar Hoerr, Florian von der Mülbe, Hans Georg Rammensee, Günther Jung, and Steve Pascolo in 2000 and is headquartered in Tübingen, Germany. | Director/Board Member | - | - |
Arix Bioscience /Venture Capital/
 Arix Bioscience /Venture Capital/ Investment ManagersFinance Arix Bioscience /Venture Capital/ (Arix Bioscience) is a venture capital subsidiary of Arix Bioscience Plc founded in 2015 by Christopher Thomas Evans, Jonathan M. Peacock and Joseph Anderson. The firm is headquartered in London, United Kingdom with an additional offices in New York. | Director/Board Member | 01/08/2022 | - |
Historique de carrière de Debra Stephanie Barker
Anciens postes connus de Debra Stephanie Barker
| Sociétés | Poste | Début | Fin |
|---|---|---|---|
| SPEXIS AG | Chief Tech/Sci/R&D Officer | 01/05/2017 | 31/12/2018 |
| NOVARTIS AG | Corporate Officer/Principal | - | - |
Formation de Debra Stephanie Barker
| King's College London | Graduate Degree |
| Queens' College Cambridge | Doctorate Degree |
Statistiques
Internationale
| Royaume-Uni | 6 |
| Suisse | 4 |
| Allemagne | 3 |
Opérationnelle
| Director/Board Member | 7 |
| Independent Dir/Board Member | 2 |
| Chief Tech/Sci/R&D Officer | 1 |
Sectorielle
| Health Technology | 8 |
| Consumer Services | 3 |
| Finance | 3 |
Fonctions occupées
Actives
Inactives
Sociétés cotées
Entreprise privées
Sociétés liées
| Sociétés cotées | 6 |
|---|---|
| NOVARTIS AG | Health Technology |
| SPEXIS AG | Health Technology |
| DESTINY PHARMA PLC | Health Technology |
| BERGENBIO ASA | Health Technology |
| ARIX BIOSCIENCE PLC | Finance |
| CUREVAC N.V. | Health Technology |
| Entreprise privées | 3 |
|---|---|
CureVac SE
CureVac SE BiotechnologyHealth Technology CureVac SE engages in the development of tumor immunotherapy. Its pipeline include mRNA-based Cancer Immunotherapies; Protein-based therapies; and mRNA-based Prophylactic Vaccines. The company was founded by Ingmar Hoerr, Florian von der Mülbe, Hans Georg Rammensee, Günther Jung, and Steve Pascolo in 2000 and is headquartered in Tübingen, Germany. | Health Technology |
Hutman Diagnostics AG
Hutman Diagnostics AG Medical SpecialtiesHealth Technology Hutman Diagnostics AG is a Swiss company that specializes in the development and management of in vitro diagnostics products. | Health Technology |
Arix Bioscience /Venture Capital/
Arix Bioscience /Venture Capital/ Investment ManagersFinance Arix Bioscience /Venture Capital/ (Arix Bioscience) is a venture capital subsidiary of Arix Bioscience Plc founded in 2015 by Christopher Thomas Evans, Jonathan M. Peacock and Joseph Anderson. The firm is headquartered in London, United Kingdom with an additional offices in New York. | Finance |
- Bourse
- Insiders
- Debra Stephanie Barker
- Expérience
